# Effects of GLP-1 and GIP on cholinergic-induced contractility in isolated jejunal muscle from obese patients with and without type 2 diabetes mellitus

**Authors:** Mantas Malinauskas, Darius Stukas, Kristina Rysevaite-Kyguoliene, Rita Gudaityte, Limas Kupčinskas, Anna Casselbrant, Lina Jankauskaite, Almantas Maleckas

PMC · DOI: 10.3389/fphys.2025.1734360 · Frontiers in Physiology · 2026-01-05

## TL;DR

This study investigates how GLP-1 and GIP affect intestinal muscle contractions in obese patients with and without type 2 diabetes.

## Contribution

The study reveals altered incretin signaling and muscle contractility in T2DM, suggesting a disrupted local environment affecting intestinal motility.

## Key findings

- GLP-1 receptors were found in smooth muscle nuclei and enteric ganglia, while GIP receptors were in both muscle layers.
- T2DM patients showed increased GIPR and DPP-4 expression and activity, with reduced GIP protein levels.
- GLP-1 inhibited circular muscle contractions in both groups, while GIP had no effect.

## Abstract

Intestinal dysmotility in type 2 diabetes mellitus (T2DM) may involve impaired cholinergic and incretin-mediated regulation. This study compared cholinergic-induced jejunal contractility and evaluated the effects of Glucagon like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) in relation to the expression of these peptides, their receptors, and Dipeptidyl peptidase 4 (DPP-4) in jejunal muscle of obese patients with and without T2DM.

Jejunal samples were collected from 32 obese patients undergoing bariatric surgery (14 with and 18 without T2DM). Jejunal muscular tissue was examined for expression of GLP-1, GIP, and for expression and localization of DPP-4 and incretin receptors (GLP-1R and GIPR). In addition, DPP-4 enzymatic activity was quantitatively assessed. Contractility of circular and longitudinal muscle strips was assessed in vitro following bethanechol stimulation, with or without GLP-1 or GIP.

GLP-1 receptors were detected in smooth muscle nuclei and enteric ganglia, while GIP receptors localized to both muscle layers. DPP-4 was present in neural and muscular compartments. In T2DM, GIPR and DPP-4 expression and activity were increased, while GIP protein was reduced. GLP-1 protein levels tended to be higher. Longitudinal muscle contractility independent of neural input was reduced in T2DM. GLP-1 selectively inhibited circular muscle contractions in both groups, whereas GIP had no effect.

This study demonstrates that reduced cholinergic activity in longitudinal muscle, lower GIP, and increased GLP-1 in T2DM indicate a shifted local incretin environment that may collectively suppress jejunal contractility.

## Linked entities

- **Proteins:** GCG (glucagon), GIP (gastric inhibitory polypeptide), GLP1R (glucagon like peptide 1 receptor), GIPR (gastric inhibitory polypeptide receptor)
- **Chemicals:** bethanechol (PubChem CID 2370)
- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, GIP (gastric inhibitory polypeptide) [NCBI Gene 2695], DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, GIPR (gastric inhibitory polypeptide receptor) [NCBI Gene 2696] {aka PGQTL2}
- **Diseases:** Intestinal dysmotility (MESH:D007410), T2DM (MESH:D003924), obese (MESH:D009765)
- **Chemicals:** bethanechol (MESH:D018723)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12812689/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12812689/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12812689/full.md

---
Source: https://tomesphere.com/paper/PMC12812689